종합 밸류에이션 구간 · 보수적 HK$31–HK$34 / 적정 HK$47–HK$64 / 낙관적 HK$87–HK$95. HK$46.7 기준, 보수적 구간과 적정 구간 사이.
보고서 발행 시 HK$48.3（2026년 6월 17일）
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
연혁
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
업계 내 위치
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.